|
Marker
|
Primary comparisona
|
Secondary comparisonb
|
|---|
|
CMVs + (n = 37)
|
CMV+ (n = 37)c
|
P value
|
CMVs− (n = 36)
|
CMV+ (n = 36)c
|
P value
|
|---|
|
Two days before CMV reactivation onset (t = −2)
|
|
IL-6
|
4.4 (3.9–5.4)
|
4.3 (3.3–4.9)
|
0.08
|
4.3 (3.7–5.2)
|
4.3 (3.0–4.7)
|
0.22
|
|
IL-8
|
3.6 (2.9–4.1)
|
3.3 (2.7–3.9)
|
0.35
|
3.5 (2.9–4.7)
|
3.4 (2.8–4.1)
|
0.23
|
|
IL-18
|
6.5 (5.9–6.9)
|
6.4 (5.9–6.6)
|
0.46
|
6.3 (5.9–6.7)
|
6.4 (5.9–6.7)
|
0.77
|
|
IP-10
|
6.5 (6.0–7.0)
|
6.3 (5.9–6.8)
|
0.13
|
6.3 (5.8–7.0)
|
6.3 (5.9–6.8)
|
0.68
|
|
N-elastase
|
10.6 (10.3–11.1)
|
10.8 (10.2–11.0)
|
0.96
|
10.7 (10.5–11.1)
|
10.7 (10.2–11.0)
|
0.42
|
|
IL-10
|
2.1 (1.4–3.3)
|
2.4 (2.0–3.1)
|
0.60
|
2.3 (1.6–3.2)
|
2.5 (1.9–3.1)
|
0.36
|
|
IL-1RA
|
6.4 (5.8–7.3)
|
6.2 (5.7–7.0)
|
0.55
|
6.4 (5.7–6.9)
|
6.5 (5.7–7.1)
|
0.63
|
|
Day of CMV reactivation onset (t = 0)
|
|
IL-6
|
4.2 (3.1–5.0)
|
3.9 (3.1–4.4)
|
0.25
|
4.1 (3.6–4.9)
|
3.8 (3.3–4.3)
|
0.16
|
|
IL-8
|
3.5 (2.7–4.3)
|
3.1 (2.5–4.0)
|
0.36
|
3.6 (2.5–4.5)
|
3.2 (2.5–3.8)
|
0.16
|
|
IL-18
|
6.4 (5.8–6.8)
|
6.2 (5.8–6.8)
|
0.67
|
6.3 (5.8–6.7)
|
6.2 (5.8–6.8)
|
0.89
|
|
IP-10
|
6.3 (5.9–6.8)
|
6.4 (5.9–6.7)
|
0.75
|
6.2 (5.8–6.8)
|
6.5 (5.9–7.0)
|
0.46
|
|
N-elastase
|
10.3 (10.1–10.8)
|
10.7 (10.2–11.0)
|
0.11
|
10.7 (10.3–10.9)
|
10.7 (10.2–11.0)
|
0.85
|
|
IL-10
|
2.0 (1.6–3.0)
|
2.5 (1.9–2.9)
|
0.35
|
2.0 (1.6–2.7)
|
2.6 (1.9–3.0)
|
0.08
|
|
IL-1RA
|
6.4 (5.4–7.1)
|
6.4 (5.5–7.0)
|
0.81
|
6.3 (5.5–7.2)
|
6.4 (5.4–6.9)
|
0.54
|
- Abbreviations: CMVs+ cytomegalovirus (CMV) seropositive without reactivation, CMV+ CMV reactivation, CMVs− CMV seronegative, IL interleukin, IP-10 interferon-gamma induced protein-10, N neutrophilic, RA receptor antagonist. Biomarker levels (in picograms per milliliter) were natural log-transformed and presented as median (Q1–Q3). Measurements were performed 2 days before CMV viremia onset and at the day of onset (defines t = 0 in viremia patient and corresponding ICU length of stay until that day determines t = 0 in matched patient without reactivation)
- aIn the primary comparison, patients with CMV reactivation were compared with matched CMV seropositive patients without reactivation
- bIn the secondary comparison, patients with CMV reactivation were compared with matched CMV seronegative patients
- cTwenty-eight patients with CMV reactivation are included in both matched comparisons
